Choose a country below to begin
- EU-M4all (formerly Article 58)
- PRIME (PRIority MEdicines)
- EMA Accelerated Assessment
- EMA Adaptive Pathways
- EMA Advanced Therapy Medicinal Products
- EMA Marketing Authorisation under Exceptional Circumstances
- EMA Conditional Marketing Authorisation
- Opening our Procedures at EMA to Non-EU authorities (OPEN)
- EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines
- PRIME (PRIority MEdicines)
- EMA Accelerated Assessment
- EMA Adaptive Pathways
- EMA Advanced Therapy Medicinal Products
- EMA Marketing Authorisation under Exceptional Circumstances
- EMA Conditional Marketing Authorisation
- Opening our Procedures at EMA to Non-EU authorities (OPEN)
- EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines
- Innovative Licensing and Access Pathway (ILAP)
- European Commission (EC) Decision Reliance Procedure
- Decentralised and mutual recognition reliance procedure for marketing authorisations (MRDCRP)
- Conditional Marketing Authorisation Applications (CMA)
- Great Britain Marketing Authorisations under exceptional circumstances
- 150-day assessment for national applications for medicines
- Orphan medicinal products
- European Commission (EC) Decision Reliance Procedure
- Decentralised and mutual recognition reliance procedure for marketing authorisations (MRDCRP)
- Conditional Marketing Authorisation Applications (CMA)
- Great Britain Marketing Authorisations under exceptional circumstances
- 150-day assessment for national applications for medicines
- Orphan medicinal products